Renalytix announces the appointment of Catherine Coste to the Company’s Board of Directors, effective June 30, 2023. Ms. Coste was also appointed as the Non-Executive Chair of the Audit Committee and a member of the Renumeration Committee. Coste has extensive financial experience having retired from Deloitte and Touche in 2020, where she was a senior partner and served as one of Deloitte’s life sciences industry executive leaders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNLX:
- Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
- Renalytix Skyrockets on FDA Approval for AI-Powered Testing Platform in the U.S.
- Renalytix price target raised to $5.00 from $3.50 at BTIG
- FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
- Renalytix says FDA grants De Novo marketing authorization for KidneyIntelX.dkd